Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...